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Abstract
Background: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained
unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to
defeat what is now the world’s greatest infectious disease killer.
Methods: We describe the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP) as a novel hybrid
phase II/III trial design to accelerate regimen development. In the Phase IIC STEP trial, the experimental regimen is
given for the duration for which it will be studied in phase III (presently 3 or 4 months) and patients are followed for
clinical outcomes of treatment failure and relapse for a total of 12 months from randomisation. Operating characteristics
of the trial design are explored assuming a classical frequentist framework as well as a Bayesian framework with flat and
sceptical priors. A simulation study is conducted using data from the RIFAQUIN phase III trial to illustrate how such a
design could be used in practice.
Results: With 80 patients per arm, and two (2.5 %) unfavourable outcomes in the STEP trial, there is a probability of 0.99
that the proportion of unfavourable outcomes in a potential phase III trial would be less than 12 % and a probability of
0.91 that the proportion of unfavourable outcomes would be less than 8 %. With six (7.5 %) unfavourable outcomes,
there is a probability of 0.82 that the proportion of unfavourable outcomes in a potential phase III trial would be less
than 12 % and a probability of 0.41 that it would be less than 8 %. Simulations using data from the RIFAQUIN trial show
that a STEP trial with 80 patients per arm would have correctly shown that the Inferior Regimen should not proceed to
phase III and would have had a high chance (0.88) of either showing that the Successful Regimen could proceed
to phase III or that it might require further optimisation.
Conclusions: Collection of definitive clinical outcome data in a relatively small number of participants over only
12 months provides valuable information about the likelihood of success in a future phase III trial. We strongly believe
that the STEP trial design described herein is an important tool that would allow for more informed decision-making
and accelerate regimen development.
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Background
New regimens are urgently needed for the treatment of
tuberculosis (TB). The current standard of care, a 6-
month four-drug regimen, has been in use for decades.
Under optimal clinical trial conditions it can achieve a
durable cure in 92 % of patients [1]; in practice, approxi-
mately 10 % of patients are forced to stop treatment pre-
maturely owing to toxicity or because life circumstances
present challenges to prolonged adherence to supervised
treatment. Many of these patients will later experience
relapse and, under programme settings, completion rates
(a proxy for cure) are closer to 80–85 % [2]. Thus, the
standard regimen is inadequate to control the epidemic
and shorter, simpler regimens are needed to defeat what
is now the world’s greatest infectious disease killer [2].
Exciting progress has been made, with two com-
pounds in different classes (bedaquiline and delamanid)
receiving accelerated approval by regulators for the
treatment of multi-drug resistant TB (MDR-TB) since
2012 [2]. In addition, there has been growing interest in
optimising old TB drugs [3] and repurposing drugs
with other indications that were previously thought to
have limited activity against TB [4, 5]. A number of
clinical trials of shorter regimens combining new and
old drugs are ongoing (ClinicalTrials.gov identifiers
NCT02410772, NCT02581527 and NCT02342886). In-
novative trial designs originally developed in oncology,
including the multi-arm multi-stage design (MAMS)
that allows for poorly performing arms to be stopped
early, have been implemented in TB phase II trials with
some success [6, 7]. There has, however, been no
change in the treatment of drug-sensitive TB for more
than 40 years. Most recently, three major international
multicentre phase III trials demonstrated that four dif-
ferent 4-month regimens did not provide as good a
standard of care as the 6-month regimen [1, 8, 9].
Antibiotics, and in particular those used for the treat-
ment of TB, were some of the first drugs evaluated system-
atically in medicine. While establishing the composition of
anti-TB first-line treatment is often thought to be the first
example of evidence-based medicine or ‘rational therapeu-
tics’ [10, 11], this feat was achieved largely empirically
through a series of studies that we would now define as
phase III trials [12]. Thus, there has been no established
pathway for clinical development in TB, and the approach
put forward by drug developers has been instituted only in
the last 10–15 years. In fact, no new compound has been
approved for the treatment of drug-sensitive TB since the
disease was declared a global emergency by the World
Health Organization in 1993, with the exception of inter-
mittent low-dose rifapentine in the continuation phase of
treatment [13], which has been implemented only in a few
low-incidence settings. The accelerated approvals of the
two new drugs for MDR-TB, bedaquiline and delamanid,
were based on data from phase II trials only. This was pos-
sible because these trials employed surrogate endpoints
that were considered likely to reflect clinical outcomes
[14] and because MDR-TB treatment outcomes with
the current standard of care are so poor (54 % cure
[15]) and the need for new medicines so acute. Full ap-
proval will only be achieved once phase III trials are
completed successfully. The accelerated approval frame-
work with the US and EU regulators could not be used for
drug-sensitive TB because there is an established and
highly effective, albeit prolonged, treatment. Furthermore,
such accelerated approval mechanisms are not often avail-
able for many regulators outside the US and the EU.
Clinical development of new treatments is conventionally
split into three phases. Phase I trials are first-in-human
studies aimed at exploring safety, pharmacokinetics, and
relevant drug-drug interactions [16]. The safety of the par-
ticipants (often healthy volunteers) is the overwhelming
primary concern because incidence and the magnitude
of toxicities cannot be readily predicted by preclinical
toxicology studies, and unexpected serious adverse
events not seen in animal studies do sometimes occur
[17]. Phase III trials are large and expensive multicentre
randomised studies that are designed to provide con-
firmatory evidence that a new treatment is safe and effi-
cacious. Thus, the objectives of the phase III trial are to
provide adequate evidence to convince regulators to ap-
prove the treatment for the disease in question and to
change policy and practice. In between these two poles
of development is a critical area: phase II or ‘middle de-
velopment’ [18], where the treatment is given to indi-
viduals with the target disease with the objectives of
identifying an optimal therapeutic dose or doses, exploring
and establishing safety in a larger group of participants,
and generating efficacy data (often on intermediate end-
points) sufficient to provide the confidence needed to jus-
tify a phase III trial. Because TB is treated with regimens
rather than individual drugs, an additional goal of middle
development is to optimise and select those combina-
tions with the highest likelihood of success in phase III
treatment-shortening trials.
Middle development for TB drugs typically follows a
sequential two-step or three-step pathway. The first step
is a 14-day monotherapy trial (a new drug can only be
given for a maximum of 14 days as monotherapy owing
to the risk of acquiring drug resistance), which is used to
demonstrate the microbiological activity of the agent
alone at different doses. This is often followed by a 7-
day to 14-day study of drugs in combination. These tri-
als are followed by longer-duration studies of drugs in
combination (traditionally 8 weeks). An example of a
development pathway is that of pretomanid (PA-824),
first evaluated as monotherapy, then in combination in
14-day and 8-week studies [19–23]. The 14-day studies
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are considered phase IIA and 8-week studies as phase IIB,
and in each case all patients are given standard treatment
after completing the experimental therapy so that the total
duration of treatment is not less than the standard
6 months. The primary endpoints of such studies are
microbiological intermediate endpoints, that is, measuring
the speed at which bacilli are killed using serially collected
sputum during the first days and weeks of treatment, and
include the decline in the number of colony-forming units
growing on solid culture media [23], increase in time to
positivity in liquid culture media [23], time to stable nega-
tive culture conversion [3], or proportion of participants
with negative sputum cultures at a specific time during
treatment [24]. Killing bacilli during a course of treatment
is a complex process that is not well understood. It has
been proposed that different drugs act on up to four dif-
ferent sub-populations of bacilli, because drug activity
may depend on the metabolic state of the organism and
the compartment in which the organism resides in the
infected host [25]. Some drugs, such as isoniazid, are
thought to act earlier, targeting metabolically active,
rapidly multiplying organisms. Others, such as pyrazina-
mide and rifampicin, are believed to act later, when the
hardest-to-kill bugs must be eradicated. Penetration of
different drugs into the lesions where the bacilli reside is
another area that affects the timing and extent of drug
activity [26]. For this reason, there is limited value in only
measuring the activity of a dose or a regimen during the
first 14 days to identify the combinations to advance from
phase IIA to phase IIB studies [27], and the activity may
depend on the drug’s mechanism of action and pharmaco-
kinetic characteristics. For example, only a small effect
was seen with bedaquiline in an initial 7-day study [28],
but in a follow-on 14-day trial that included loading doses,
clear activity was demonstrated [29]. Clofazimine had no
effect over 14 days at tested doses [22]. Nevertheless, both
bedaquiline and clofazimine have important roles in com-
bination with other agents in longer duration randomised
clinical trials for the treatment of MDR-TB [30, 31]. In
practice, the 14-day and 8-week studies merely demonstrate
that the drug or regimen has some anti-mycobacterial
activity in humans, but both yield incomplete efficacy or
safety data. More importantly, even microbiological activity
over 8 weeks has a limited role in decision-making for
advancing regimens to phase III trials [32–35]. The modest
benefits in microbiological activity with moxifloxacin seen
in 8-week studies were confirmed in the REMoxTB
phase III trial [1], but these benefits did not translate
into activity sufficient to cure patients in just 4 months.
Stated directly, many regimens with impressive micro-
biological activity over 2 or 8 weeks of treatment are
not sufficiently active to allow for treatment shortening,
demonstrated by high rates of relapse [1, 8, 9, 12]. Fur-
thermore, safety data generated in phase II trials are
valuable but limited given the shorter duration of use
over only 8 weeks.
The model of clinical development employed by the
pharmaceutical industry assumes a limited number of
drug candidates and is focused on gathering adequate
data to inform go/no-go decisions along the develop-
ment pathway so that promising compounds are ad-
vanced efficiently and unpromising ones are abandoned
early. In general, about 60–70 % of drugs that enter
phase III trials are successfully licensed, but the success
rate depends highly on the disease entity and drug class
[36]. This model has informed many of the common ap-
proaches in TB regimen development, with doses and
regimens selected based on early clinical studies and car-
ried through the development process until they fail.
This pathway for developing regimens for TB has not
been successful to date. Because TB is a major public
health problem with drug development funded largely
through public and philanthropic sources [37], the focus
of middle development should be the efficient identifica-
tion and testing of those regimens that are most likely to
shorten TB therapy rather than excessive attention to
particular drugs or combinations. A barrier to this is the
panoply of potential old, repurposed, and new drugs,
which results in a large number of possible three-drug
and four-drug combination regimens that might lead to
shorter, simpler regimens.
To redress this over-reliance on 14-day and 8-week
endpoints and to facilitate this broader perspective on
the middle development of TB drugs and regimens, we
propose a new hybrid phase II/III trial design: the Phase
IIC Selection Trial with Extended Post-treatment follow-
up (STEP). We believe that the Phase IIC STEP trial de-
sign will help to bridge the gap between phase II and
phase III by improving the quality and relevance of data
generated in middle development. This improved evidence
base prior to phase III will allow for informed decisions
for selecting novel regimens to proceed to confirmatory
trials and will reduce the risk of expensive phase III
failures. In this paper we describe the STEP design and ex-
plore its operating characteristics under typical scenarios.
We have also conducted a simulation study using data
from a large, recently completed phase III trial to illustrate
how such a design could be used in practice.
Methods
STEP trial design
We define a STEP trial as one with the following features:
1. The novel regimen is given for the duration for
which it is intended to be studied in phase III
(presently 3 or 4 months).
2. Treatment is stopped after experimental therapy is
completed (provided there is sufficient confidence
Phillips et al. BMC Medicine  (2016) 14:51 Page 3 of 11
that it is safe to do so from evidence collected in the
study itself or in previous studies).
3. Patients are followed for clinical outcomes of
treatment failure and relapse for a total of
12 months from randomisation.
This can be contrasted with the current phase IIB de-
sign (Fig. 1). A STEP trial is designed with a similar sam-
ple size to a standard phase IIB study with the primary
outcome defined in typical fashion—time to culture con-
version or decline in bacillary load over time [23, 38].
However, because the regimen is given for its intended
duration, and patients are followed for a total of 12 months
from randomisation, data on the definitive clinical end-
point, status at 12 months post-randomisation (a compos-
ite outcome of treatment failure and relapse) is also
collected. This composite outcome is the same as that
used in confirmatory phase III trials [1, 8]. Twelve months
of follow-up is considered adequate because more than
75 % of relapses occur within 6 months of stopping
treatment [39]; 18 months of follow-up would consider-
ably prolong the duration of the trial without significantly
enhancing the knowledge gained. While the precision in
this composite unfavourable outcome will be low because
unfavourable outcomes are rare and phase II trials are
relatively small (and it therefore should formally be a
secondary rather than primary outcome in the trial), it will
provide invaluable information to guide decisions about
further clinical development of the regimen. Equally im-
portant are the longer-term safety and tolerability data,
both during treatment and following completion of
treatment. A STEP trial could be considered as a pilot
phase III trial, with the collection of similarly rich data on
clinically relevant outcomes but at a much lower sample
size and cost. Results of a STEP trial may support several
potential development strategies: direct advancement for
evaluation in a definitive phase III trial, further phase II
work to optimise the doses or change the regimen
components, pharmacokinetic-pharmacodynamic (PK-PD)
assessments to understand underperforming regimens or
identify populations that are not seeming to benefit,
or cessation of development activities altogether.
Statistical methods
Sample sizes for TB phase IIB trials have varied from 60
to 100 per arm, with this number considered to be
adequate to demonstrate important differences in inter-
mediate endpoints such as time to culture conversion or
slope of decline in bacillary load [23, 38, 40]. We there-
fore selected this range for a STEP trial to explore the
operating characteristics for the important secondary
outcome of an unfavourable outcome. This allows us to
show what could be achieved without an increase in
sample size as compared to a phase IIB trial. Inference
from this secondary outcome is considered first from a
more familiar classical frequentist perspective and second
from a Bayesian framework, which lends itself more to the
sort of decision-making necessary for clinical development
of regimens.
In the frequentist framework, hypothesis testing for
the secondary outcome of an unfavourable outcome was
set up as a 90 % two-sided confidence interval to ex-
clude a specified proportion at the upper bound. The
power for a given sample size, the proportion to be
excluded at the upper bound, and the assumed true
proportion were estimated from standard sample size
formulae for a one-sample proportion [41]. A 90 %
confidence interval (corresponding to a 5 % one-sided
level of significance) was chosen given that this is a
phase II trial with the objective of collecting evidence
to guide decisions for future confirmatory trials, although
other TB phase II trials more often use 95 % confidence
intervals [24].
a
b
Fig. 1 Comparison of standard phase IIB design (a) with the STEP
design (b)
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In the Bayesian framework, the posterior distribution
of the proportion of unfavourable outcomes was calcu-
lated using a binomial distribution for the observed data
and using both flat and sceptical beta conjugate priors.
A flat prior assigns equal (low) probability for each un-
favourable outcome proportion from 0 % to 100 %. The
sceptical prior was chosen as having a fairly wide distri-
bution with a higher density around a 20 % proportion
of unfavourable outcomes, which would be an unsuitable
regimen for evaluation in a phase III trial, and a lower
density for very high proportions of unfavourable out-
comes (extremely unlikely for a regimen selected for
phase II evaluation). A prediction of the number of un-
favourable outcomes for a future phase III trial was cal-
culated from the predictive posterior distribution, which
follows a beta-binomial distribution [42]. The predictive
probability mimics the clinical decision-making process
and provides the probability that a regimen will have an
acceptably low proportion of unfavourable outcomes in
a future phase III trial. The hypothetical phase III trial is
said to have 500 patients per arm, which is not dissimilar
to other previous and ongoing TB phase III trials.
In order to further explore the operating characteris-
tics of the STEP trial design, data were repeatedly sam-
pled without replacement from the recently completed
RIFAQUIN phase III trial, with the unfavourable out-
come as defined in the trial, censored at 12 months from
randomisation. RIFAQUIN evaluated two novel regi-
mens for the treatment of TB in seven sites across
southern Africa as compared to the standard 6-month
control [8]. RIFAQUIN included one arm that was
shown to be non-inferior to the control regimen (the
Successful Regimen) and one that did not meet criteria
for non-inferiority (the Inferior Regimen). The Successful
Regimen in RIFAQUIN was actually a 6-month regimen,
but for the purposes of illustration, we can assume that
both experimental arms were 4-month regimens. This
trial is thus useful for exploring what additional informa-
tion a STEP trial might have added had it been conducted
before the phase III trial.
Ethical permissions
The trial data from the RIFAQUIN trial used for the
simulation study were fully anonymised for the purposes
of these analyses and therefore no further ethical approval
was required. The RIFAQUIN trial received ethical ap-
proval and all patients gave informed consent, as detailed
in the primary publication [8].
Results
Power calculations in a frequentist framework
Figure 2 shows the power curves for the secondary out-
come of an unfavourable outcome under various scenarios
within the frequentist framework. With a STEP trial of 80
assessable patients per arm (Fig. 2b), there would be 80 %
power to exclude a proportion of unfavourable outcomes
of 18.3 % at the upper bound of the 90 % confidence inter-
val, or 90 % power to exclude a proportion of 19.8 %
assuming a true proportion of unfavourable outcomes of
8 %, similar to that observed with the 6-month control
regimen in recent phase III trials [1]. The same trial would
give 80 % power to exclude a proportion of unfavourable
outcomes of 9.3 % and 90 % power to exclude a propor-
tion of 10.2 % for a superior regimen with a true unfavour-
able outcome of 2 %.
Bayesian predictive probability
An alternative perspective would be to consider the
Bayesian predictive probability of the unfavourable out-
come being lower than a pre-specified threshold (p1) in
a future phase III trial with 500 patients per arm, given
the observed unfavourable outcome from the STEP trial
and incorporating prior information. This approach al-
lows for explicit incorporation of the prior confidence in
a regimen before the data are collected in the STEP trial.
Figure 3 shows three different prior distributions reflecting
a range of prior confidence from sceptical to enthusiastic.
Figure 4 shows the Bayesian predictive probability that the
proportion of unfavourable outcomes is less than a pre-
specified threshold (p1) in a potential phase III trial given a
sceptical or flat prior. With the sceptical prior and 80 pa-
tients per arm, two (2.5 %) unfavourable outcomes in the
STEP trial would mean there is a probability of 0.99 that
the proportion of unfavourable outcomes in the potential
phase III would be less than p1 = 12 % and a probability of
0.91 that the proportion of unfavourable outcomes would
be less than p1 = 8 %. With six (7.5 %) unfavourable
outcomes in the STEP trial, there is a probability of 0.82
that the proportion of unfavourable outcomes in a poten-
tial phase III would be less than p1 = 12 % and a probability
of 0.41 that it would be less than p1 = 8 %.
Results from simulations employing the RIFAQUIN
trial data
Sampling data from the RIFAQUIN trial allows us to
consider what the additional benefit of a STEP trial
would have been had it been conducted before the phase
III trial, showing how such a trial design might be used
in practice. Focusing specifically on the Bayesian formu-
lation, Fig. 5 shows the results of 10,000 random draws
from the RIFAQUIN trial data using the primary out-
come as defined in the trial censored at 12 months [8]
using a sceptical prior. Similar results with the flat prior
are shown in Fig. 6. The predictive probability is grouped
into four categories to show possible decision outcomes:
0.00 to <0.50, 0.50 to <0.75, 0.75 to <0.95, and 0.95 to 1.00
(Fig. 7). A predictive probability of <0.50 might be used to
indicate that the development of a regimen be abandoned
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(stop, red bars) and a predictive probability of >0.95 might
be used to indicate strong evidence for continuing the
regimen to a phase III trial (go, green bars). Predictive
probabilities of 0.75 to <0.95 (proceed with caution, amber
bars) might be used to indicate further optimisation is re-
quired before proceeding to evaluation in a phase III trial,
with the decision depending on other outcomes from the
STEP trial. Predictive probabilities of 0.50 to <0.75 (blue
bars) might be used to indicate changes to the regimen
should be considered before possible further re-evaluation
in a STEP trial.
Considering a STEP trial of 80 patients per arm, 100 %
of the simulated trials for the Inferior Regimen had a
predictive probability of less than 0.50 that the un-
favourable proportion in a phase III trial would be less
than p1 = 8 % (Fig. 5b) indicating this regimen should
be abandoned (red bars). In contrast, 28 % of the
Fig. 2 Power curves for excluding a proportion of unfavourable outcomes under different assumptions of the true proportion, assuming (a) 60,
(b) 80, and (c) 100 patients per arm for a STEP trial. Numbers on graphs show the proportion of unfavourable outcomes that could be excluded
at the upper bound of the 90 % two-sided confidence interval (95 % one-sided confidence interval, CI) with 80 % and 90 % power
Fig. 3 Distribution functions under various prior assumptions. The
flat prior assigns equal (low) probability for each unfavourable
outcome proportion from 0 % to 100 %. The sceptical prior assigns
a higher probability to a 20 % proportion of unfavourable outcomes (a
regimen that would not be suitable for evaluation in a phase III trial), and
a lower probability to very high or very low proportions of unfavourable
outcomes. The enthusiastic prior assigns a high probability to
proportions of unfavourable outcomes less than 10 % and lower
probabilities to proportions greater than 10 %. The sceptical prior
has a median at 26.4 % and the enthusiastic prior has a median at 3.3 %
Fig. 4 Bayesian predictive probability of the unfavourable outcome
being less than a specific threshold, p1, in a future phase III trial of
500 patients per arm, following various observed proportions of
unfavourable outcomes and patient numbers in a STEP trial of equal
treatment duration. Solid lines correspond to a sceptical prior and
dashed lines to the flat prior
Phillips et al. BMC Medicine  (2016) 14:51 Page 6 of 11
simulated trials for the Successful Regimen had a pre-
dictive probability of greater than 0.95 that the un-
favourable proportion in a phase III trial would be less
than p1 = 8 % (green bars), and 60 % for the Successful
Regimen had a predictive probability between 0.75 and
0.95 (amber bars). This shows a STEP trial would have
correctly shown that the Inferior Regimen should not
proceed to phase III (this regimen was shown to have
significantly more unfavourable outcomes than the
control arm in the RIFAQUIN phase III trial). It would also
have had a high chance (88 %) of either showing that the
Successful Regimen could proceed to phase III or that it
might require further optimisation (the Successful Regimen
was shown to be non-inferior to control in the RIFAQUIN
phase III trial). Using a larger STEP trial with 100 patients
per arm results in a greater chance of a predictive
probability of more than 0.95 (43 % of trials), as would
using a flat prior instead of a sceptical prior (Fig. 6).
Discussion
We have described how a trial with the novel Phase IIC
STEP design and a similar sample size to that commonly
used in phase IIB trials for TB regimens could be used
to provide important additional information to inform
the decision on whether to proceed to evaluation in
phase III. Furthermore, a simulation study using data
Fig. 5 Results of a simulation study using RIFAQUIN data with a
sceptical prior. Charts show the distribution of the predictive probability
of the unfavourable proportion in the phase III trial being lower than
the threshold p1 from 10,000 random draws from the RIFAQUIN trial
data for various sizes of STEP trials (60, 80, 100 per arm) and thresholds
p1 = 5 % (a), 8 % (b), and 10 % (c)
Fig. 6 Results of a simulation study using RIFAQUIN data with a flat
prior. Charts show the distribution of the predictive probability of
the unfavourable proportion in the phase III trial being lower than
the threshold p1 from 10,000 random draws from the RIFAQUIN trial
data for various sizes of STEP trials (60, 80, 100 per arm) and thresholds
p1 = 5 % (a), 8 % (b), and 10 % (c)
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from the RIFAQUIN trial demonstrated that conducting a
STEP trial first with 80 patients per arm would have led to
the correct decision in 100 % of the simulated trials to not
proceed with evaluation in a phase III trial with a regimen
that was subsequently shown to be inferior, saving cost
and reducing risk to participants. Use of such a design
could fundamentally improve our ability to choose those
regimens most likely to succeed in phase III evaluation
and help us avoid costly phase III failures.
We favour a Bayesian approach to the interpretation
of a STEP trial, but have also presented the frequentist
framework to show how this could be applied. The
Bayesian probability is easy to interpret and fits more
naturally into a decision framework for deciding whether
to move a regimen into phase III evaluation or whether
a regimen requires further optimisation. A traffic light
system for ‘stop’, ‘go,’ or ‘proceed with caution’ might be
used to improve understanding of the results. A prob-
ability of at least 0.95 for the unfavourable proportion
(p1) being less than 8 % might be considered a reason-
able threshold for progressing to a phase III trial, which
would be analogous to the 95 % confidence intervals and
5 % type I error rate commonly adopted in frequentist
hypothesis testing.
In principle, STEP trial results could be used to sup-
port subsequent trials of a different duration than that
which was studied in the STEP trial itself. A very high
predictive probability might indicate a shorter regimen
could be considered for phase III (a 3-month regimen if
a 4-month regimen was studied in the STEP trial, for ex-
ample), and a more modest predictive probability might
indicate a longer regimen should be considered for
phase III. While this paper focuses on the development
of regimens for drug-sensitive TB, a STEP trial would
also be suitable for regimens for MDR-TB where 6-
month or 9-month regimens are tested.
The Bayesian framework allows for the incorporation of
prior information. We have used and would recommend a
slightly sceptical prior rather than a flat, so-called non-
informative prior because this more accurately reflects the
likelihood of a new regimen failing in clinical develop-
ment. Our chosen sceptical prior assumes that an un-
favourable proportion of around 20 % is most likely, but
has a wide distribution and therefore has only limited im-
pact on the interpretation of the results (shown by the
closeness of the lines assuming the sceptical and flat priors
in Fig. 4). However, more sophisticated priors could be
used to formally incorporate promising preclinical as well
as any other earlier clinical trial data on efficacy into the
decision-making process. The beta prior lends itself to this
sort of approach, where the distributional parameters a
and b can be interpreted as the strength of real data with
a unfavourable outcomes and b favourable outcomes. For
example, a relapse murine study of 15 mice with only one
relapse and 14 cures could be summarised as a prior with
a Beta(0.5, 7) distribution (the enthusiastic prior in Fig. 3),
if considering data from a murine study as having half
the strength of a human study (a = 1/2 = 0.5, and b =
14/2 = 7). In such a situation, it would be appropriate
to conduct the analysis using both the sceptical and en-
thusiastic priors and compare the results.
The results regarding the secondary outcome (an
unfavourable outcome) must be considered alongside
the results of the primary outcome (killing of bacilli)
when deciding how to proceed with the regimen under
evaluation. If the predictive probability was greater than
0.75, a large increase in killing of bacilli with a new regi-
men would strengthen the decision to move to phase III
whereas only a modest increase would provide evidence
that further optimisation was needed. The results regard-
ing the intermediate outcome could also be formally
incorporated into the decision process by updating the
prior with this information in conjunction with a predic-
tion model that links the intermediate outcome with the
long-term clinical outcome (one published model uses 2-
month culture results on solid media [43]). The primary
intermediate outcome data would likely be available
before the long-term clinical unfavourable outcome data,
so this updating of the prior could be done after that
primary outcome analysis and before the long-term
clinical data were available.
There are a number of factors that will determine
whether a STEP trial could replace a traditional phase IIB
trial in TB regimen development. It would be essential to
have reasonable confidence that the drug combination
could be used safely for 3 or 4 months, based on the ad-
verse event profile and knowledge about the relationship
between the duration of treatment and risk of toxicity. It
Fig. 7 Traffic light system for interpreting the Bayesian
predictive probability
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is also necessary to have sufficient confidence in the
efficacy of a regimen and the capacity of the trial sites to
follow up patients to be secure in stopping treatment after
3 or 4 months; otherwise, trial participants are put at un-
necessary risk of relapse, with its resultant morbidity.
Where confidence is insufficient to proceed directly to a
STEP trial based on available knowledge after a smaller
14-day study, a STEP trial might still be considered after
the phase IIB trial owing to the benefits in preventing
costly phase III failure. Where the evidence preceding a
STEP trial may not be as strong as that preceding a large
phase III trial, some arms might be at unusually high risk
of failure and early relapse. In such cases, careful patient
monitoring (including regular cultures during treatment)
and frequent and efficient oversight by an independent
data monitoring committee are important features.
We believe that the richness of data from a STEP trial
supports a broader philosophy in the middle develop-
ment of ‘iterative optimisation’ where the objective of
efficiently selecting from among numerous optimised
combination regimens is met. As combinations are shown
to be effective and safe, newer drugs can be added, doses
adjusted (making fullest use of PK-PD modelling), and
drugs replaced in sequential STEP evaluation (or phase
IIB where necessary) until a regimen is identified that is
sufficiently promising to proceed to evaluation in phase
III. Indeed, competing combinations can be evaluated
side-by-side within the same multi-arm trial. A MAMS
design [7] would be appropriate to allow recruitment to
unpromising arms to be stopped early, taking into account
long-term clinical outcomes and short-term microbio-
logical outcomes, thereby enhancing efficiency. The flexi-
bility of the MAMS design also allows for adding new
arms so that sequential evaluations could be managed
within the same platform trial, an approach that has been
successful in prostate cancer trials [44].
There are a number of limitations with a STEP trial.
Additional follow-up visits are required after the end of
treatment and these incur costs and increase the duration
of the trial by 6 months, thereby delaying the start of the
phase III trial. However, a visit at the end of treatment, at
12 months post-randomisation, and a third intermediate
visit, with sputum taken for culture at each visit, would
likely be adequate to identify treatment failure and relapse
and determine 12-month cure. The simulation study using
the RIFAQUIN trial data also indicated that a slightly
larger sample size of 100 per arm might be preferable for
a STEP trial to give more information and greater
confidence in decision-making for phase III.
More work is needed to consider further extensions
of the methodology and how this might operate in
practice. A Bayesian adaptive trial design could also be
used where the prior is continually updated as data ac-
crue on both the primary intermediate outcome and
the long-term unfavourable outcome during the STEP
trial, with rules for stopping arms early. This would
allow for real-time assessment of risks and benefits to
participants [42]. The Bayesian framework has been set
up around the predictive probability of the unfavourable
proportion being lower than a pre-specified threshold (p1)
in a future phase III trial, but a more practical alternative
would be to incorporate results on the control arm from
the STEP trial and calculate the unconditional probability
of actually demonstrating non-inferiority in a future phase
III. This is known as ‘assurance’, which is a Bayesian exten-
sion of the concept of the power of a clinical trial that
more formally incorporates the uncertainty resulting from
a phase II trial [45].
The iterative approach to regimen development, in
contrast to the linear approach, may be of most value
when there are multiple promising drugs and combina-
tions to be evaluated in middle development so that the
most promising regimen or regimens can be taken for-
ward to phase III. In practice, this may be limited by the
extent to which individual drugs can be evaluated in
combination prior to regulatory approval and the limita-
tions imposed by regulators and the companies which
own the intellectual property. These limitations must be
overcome in order to improve the treatment of TB and
are being addressed in other arenas, an example being
the 3P Project [46].
We have proposed a traffic light system for the pre-
dictive probability. Our intention was to set a high bar
for moving regimens forward to phase III trials, given
that the STEP trial design was motivated by the desire
to reduce the risk of costly phase III failures. For this
reason, the relatively small sample size with the STEP
trial design means that there is a higher chance of a false
negative result, where a truly effective regimen is not im-
mediately advanced to phase III. Simulations from the
RIFAQUIN trial showed that only 28 % of STEP trials
with 80 patients per arm would have resulted in a pre-
dictive probability of greater than 0.95. Further work is
needed to evaluate whether the 0.95 threshold could be
relaxed; one approach would be to consider how this im-
pacts frequentist concepts like power and type I error
rate [47]. However, the Bayesian approach is particularly
useful here because it quantifies the likelihood of phase III
success, rather than imposing a dichotomous go/no-go
decision. As we have shown, a predictive probability of
less than 0.95 need not necessarily lead to a regimen being
abandoned, but would suggest that the regimen may re-
quire further optimisation before proceeding to phase III.
In this setting, critical evaluation of all the trial outcomes
(not just the primary endpoint) and of variability in
measurement of the primary endpoint would be essen-
tial, as would sophisticated PK-PD analyses (to see if
higher exposures improve outcomes). A STEP trial may
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have delayed the start of the RIFAQUIN trial, but we
submit that this would have been a worthwhile risk
given that it would have shown that the Inferior Regimen
should not have been advanced.
Conclusions
We have proposed the Phase IIC STEP design that (1)
yields rich, highly relevant information about treatment
outcomes that is additional and complementary to the
intermediate microbiological data typically gathered in
phase II trials and (2) facilitates iterative optimisation of
combination regimens in middle development. We have
shown that collecting definitive clinical outcome data in a
relatively small number of participants over only 12 months
does provide invaluable information about the likelihood
of success in a future phase III trial. For these reasons, we
strongly believe that the STEP design described herein is
an important tool for use in middle development for new
TB regimens that would allow for more informed decision-
making and accelerate regimen development.
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